ES2196067T3 - Metodo para atenuar la estenosis arterial. - Google Patents

Metodo para atenuar la estenosis arterial.

Info

Publication number
ES2196067T3
ES2196067T3 ES95925386T ES95925386T ES2196067T3 ES 2196067 T3 ES2196067 T3 ES 2196067T3 ES 95925386 T ES95925386 T ES 95925386T ES 95925386 T ES95925386 T ES 95925386T ES 2196067 T3 ES2196067 T3 ES 2196067T3
Authority
ES
Spain
Prior art keywords
atenuating
arterial stenosis
stenosis
atenuishing
angioplastia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95925386T
Other languages
English (en)
Inventor
D Abendschein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of ES2196067T3 publication Critical patent/ES2196067T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Paper (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Devices For Medical Bathing And Washing (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE MUESTRA UN METODO PARA ATENUAR LA ESTENOSIS DESPUES DE LA ANGIOPLASTIA DE GLOBO. EL METODO SUPONE LA ADMINISTRACION PARENTERAL A UN SUJETO DESPUES DE UNA ANGIOPLASTIA DE GLOBO DE UNA CANTIDAD EFECTIVA Y SUFICIENTE DE UN INHIBIDOR DE TRAYECTORIA DEL FACTOR DEL TEJIDO (ITFT) PARA REDUCIR LA EXTENSION DE LA RESTENOSIS. LA CANTIDAD IDEAL DE ITPF OSCILA ENTRE 0.5 MG/KG Y 6 MG/KG DURANTE UNA ADMINISTRACION PROLONGADA DE ENTRE TRES (3) Y 24 HORAS.
ES95925386T 1994-07-07 1995-07-06 Metodo para atenuar la estenosis arterial. Expired - Lifetime ES2196067T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27193094A 1994-07-07 1994-07-07

Publications (1)

Publication Number Publication Date
ES2196067T3 true ES2196067T3 (es) 2003-12-16

Family

ID=23037681

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95925386T Expired - Lifetime ES2196067T3 (es) 1994-07-07 1995-07-06 Metodo para atenuar la estenosis arterial.

Country Status (10)

Country Link
EP (1) EP0769962B1 (es)
JP (2) JP4065557B2 (es)
AT (1) ATE235252T1 (es)
AU (1) AU2953795A (es)
CA (1) CA2194443A1 (es)
DE (1) DE69530084T2 (es)
DK (1) DK0769962T3 (es)
ES (1) ES2196067T3 (es)
PT (1) PT769962E (es)
WO (1) WO1996001649A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223745C (en) 1995-06-07 2004-03-16 Chiron Corporation Method of solubilizing, purifying, and refolding protein
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
US8333913B2 (en) * 2007-03-20 2012-12-18 Idemitsu Kosan Co., Ltd. Sputtering target, oxide semiconductor film and semiconductor device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0465557A (ja) * 1990-06-28 1992-03-02 Unitika Ltd 起毛編物の製造方法
CA2049873C (en) * 1990-08-27 2001-12-04 Tze-Chein Wun Anticoagulant combination of laci and sulfated polysaccharides
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)

Also Published As

Publication number Publication date
PT769962E (pt) 2003-07-31
DE69530084D1 (de) 2003-04-30
WO1996001649A1 (en) 1996-01-25
DK0769962T3 (da) 2003-06-23
CA2194443A1 (en) 1996-01-25
DE69530084T2 (de) 2004-02-05
ATE235252T1 (de) 2003-04-15
JP4065557B2 (ja) 2008-03-26
JP2008007512A (ja) 2008-01-17
EP0769962A1 (en) 1997-05-02
JPH10502639A (ja) 1998-03-10
AU2953795A (en) 1996-02-09
EP0769962B1 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
CA2267760A1 (en) Stent lining
TR200200129T2 (tr) Hepatit C inhibitörü tri-peptidler
ATE395418T1 (de) Alpha(1,3)galactosyltransferase-negatives schwein
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
DK1014888T3 (da) Middel til placering af en protese
DK20290D0 (da) Formuleringer med forsinket afgivelse
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
EP0420600A3 (en) Use of protease inhibitors as antiexudative, antiphlogistic and antimicrobial agents
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
CA2200480A1 (en) New use of prostaglandins
NO924066D0 (no) Terapeutisk middel
ES2196067T3 (es) Metodo para atenuar la estenosis arterial.
ATE174588T1 (de) 4-arylisoindol-analgetika
ECSP045075A (es) Endoprotesis vasculares ("stents")"
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
CA2053566A1 (en) Biological cycle affecting goggles
DE69329649D1 (de) Verbesserte antiandrogene
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
NZ336249A (en) parenteral composition of a dihydropolyprenol and a pharmaceutically acceptable oil
GT199900039A (es) Combinaciones de estatina-inhibidor de mmp.
ES2105290T3 (es) Composicion herbicida.
ES8501757A1 (es) Procedimiento para la obtencion de 5-diazacicloalquilimidazo-(1,2-c)-(1,3)-benzodiazepinas.
ITMI922657A1 (it) Composizione terapeutica per uso rettale a base di flunisolide e/o dei relativi esteri per il trattamento di disordini intestinali a carattere infiammatorio
AR013138A1 (es) Uso de derivados de azuleno como inhibidores de las metaloproteinas
ES2129047T3 (es) Metodo para mejorar la memoria y la calidad de vida.